Returns

As at 31 October 2026	1m %	3m %	1y %	3y % pa	5y % pa	Since inception % pa (Nov 13)
Gross	-6.9	9.8	4.4	8.9	0.0	10.4
Net of Fees	-6.9	9.8	4.4	8.9	0.0	9.6
S&P Biotechnology Select Industry Index (converted to AUD)	-1.6	6.1	29.7	29.0	6.2	10.0

Portfolio Composition

NAV per share	% in AUD cash	% shares in USD	% shares in AUD
1.90*	21	62	17

Commentary

October continues with markets focussed on AI related trade whilst the rest of the market languished. There was increasing volatility towards the end of the month (and the start of November) in the wake of developments in US politics. The CE portfolio gave up all the gains made in September over the last 2 days of October. As at time of writing, markets are even more volatile, with the Korean sharemarket shut down due to triggering of daily price limits.

We have more than ample experience over nearly 3 decades to weather stockmarket turbulences. The portfolio is still relatively conservative, with 21% cash plus 10% of the portfolio in stocks currently subject to takeover bids. Reporting season has also been largely positive for our CE portfolio companies (eg West Pharmaceuticals, Repligen, Transmedics, Sophia Genetics, etc). Funding and activity for the life sciences and healthcare sector remains robustly in recovery, with positive early earnings results from the major companies.

Thank you for your continued trust and confidence in us.

Regards

Peter Phan

Portfolio Manager

Appendix 1: Gross Monthly Returns

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD	SPSIBI
2022	-5.5	0	0.5	-4.5	1.0	-0.5	2.0	-1.0	-5.0	2.0	4.0	-0.5	**-7.5**	-20.4
2023	2.0	2.0	-1.2	1.8	-2.3	0.0	5.4	-5.7	-3.0	-7.5	6.1	6.4	**2.9**	6.9
2024	1.2	1.0	0.5	-7	2.5	-1.8	0.0	3.1	0.0	-3.5	2.5	1.2	**-1.2**	10.6
2025	4.8	-2.5	-6.6	2.5	2.0	1.0	1.8	-3.0	7.4	4.6	-2.7	-4.9	**2.4**	26.0
2026	-0.5	-2.4	-8.0	0.0	4.0	14.0	-3.0	12.7	4.6	-6.9			**13.1**	22.2

SPSIBI = S&P Biotechnology Select Industry Index (converted to AUD)

Appendix 2: Portfolio Composition

Functional Sub-Sectors*	% of portfolio
Cash	21.0%
Software/Data	17.0%
Tools and Devices	14.0%
Bioprocessing	18.0%
Genomics	5.0%
Radiopharma	11.0%
Drug Discovery	7.0%
Legacy- Financial Industry	7.0%

Industry Sectors*	% of portfolio
Cash	21.0%
Life Sciences	39.0%
Healthcare	33.0%
Legacy- Financial Industry	7.0%

Business Model Categories*	% of portfolio
Cash	21.0%
Picks and Shovels	66.0%
Services	10.0%
Infrastructure	0.0%
Legacy- Financial Industry	7.0%

Appendix 3: CE NAV

CE commenced on 1 November 2013 with shares issued at $1 per share, backed by $1 of cash per share.

CE NAV is after payment of dividend and director fees in calendar month February of each year. These payments "reset" the NAV as follows:

(a) 1.52 to 1.34 in Feb 2017
(b) 1.46 to 1.39 in Feb 2018
(c) 1.39 to 1.39 in Feb 2019
(d) 2.29 to 2.10 in Feb 2020
(e) 2.53 to 2.25 in Feb 2021
(f) 2.03 to 1.77 in Feb 2022
(g) 1.77 to 1.65 in Feb 2023
(h) 1.65 to 1.65 in Feb 2024
(i) 1.72 to 1.72 in Feb 2025
(j) 1.67 to 1.67 in Feb 2026